Pfizer Stock News

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer''s Paxlovid as the first antiviral pill to treat COVID-19 at home.

Shares of Pfizer Inc. were up 1.6% in trading on Wednesday after the Food and Drug Administration authorized the company''s COVID-19 antiviral, bringing to market the first at-home COVID-19 pill during the course of the pandemic. Pfizer''s drug, Paxlovid, can be used to treat people who are at least 12 years old with confirmed mild or moderate cases of COVID-19 and are at high risk for disease progression. Patients should begin treatments within 5 days of the first symptoms; the treatment regimen consists of three tablets taken twice a day for five days. The emergency-use authorization is based on data from a clinical trial that found Paxlovid can reduce the risk of hospitalization and death by 88%. Pfizer''s stock has gained 63.3% so far this year, while the broader S&P 500 is up 23.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Pfizer''s pill was highly effective at preventing hospitalizations and deaths among people who recently got COVID-19.

A Pfizer pill for coronavirus that can prevent serious illness was authorized by the Food and Drug Administration on Wednesday.

The U.S. has authorized the first pill against COVID-19, a Pfizer drug that Americans can take at home to reduce the risk of hospitalization and death

The Pfizer/BioNTech coronavirus vaccine has been approved for use in vulnerable primary school children.

Written By Gerald Gekara | | Pfizer is joining the medicinal marijuana sector, after banking on a cannabis-based bowel illness treatment firm. Arena Pharmaceuticals, a clinical-stage business, signed an agreement with the biotechnology company to acquire a total ownership stake worth $6.7 billion. According to the agreement, Pfizer will get all shares at $100 per [] The post Pfizer Goes Into Medical Marijuana Production appeared first on Uzalendo News .

The JCVI has recommended children in this group are offered two doses of the Pfizer vaccine.

France has canceled its order for Merck’s new Covid-19 antiviral treatment molnupiravir due to its weak performance in trials, and ordered Pfizer’s Paxlovid instead, Health Minister Olivier Veran said on Wednesday. Read Full Article at RT.com

Breaking: Covid vaccine approved for vulnerable children aged five to 11 in the UK. BREAKING NEWS The Covid vaccine from Pfizer/BioNTech has been approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA) for vulnerable children aged five to 11 in the UK. At present, Covid jabs are only given to children [] The post Breaking: Covid vaccine approved for vulnerable children aged five to 11 in the UK appeared first on Euro Weekly News Spain .

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) said on Wednesday it approved the use of the Pfizer/BioNTech COVID-19 vaccine for children aged between 5 and 11. The age

Only those who are clinically at-risk will be offered a vaccine.

A new formulation of the Pfizer/BioNTech coronavirus vaccine has been approved for use in children aged five to 11.

The US Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as Wednesday, Bloomberg News reported on Tuesday, citing people familiar with the matter. The post US FDA set to authorise Pfizer, Merck COVID-19 pills this week: Bloomberg News appeared first on SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa''s news leader. .

Early this month, Pfizer CEO Albert Bourla said fourth Covid vaccine doses may be needed sooner than expected to fight the Omicron variant. However, that may no longer be necessary if the latest report from the US Army were to [] The post One Jab to Rule Them All: US Military Scientists Develops a Single Vaccine Effective Against All COVID and Future Covid Variants, Researchers Say appeared first on Tech News | Startups News .